PMID- 35491773
OWN - NLM
STAT- MEDLINE
DCOM- 20220503
LR  - 20240213
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Print)
IS  - 1574-0153 (Linking)
VI  - 33
IP  - 4
DP  - 2022
TI  - The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.
PG  - 449-465
LID - 10.3233/CBM-210382 [doi]
AB  - The Early Detection Research Network's (EDRN) purpose is to discover, develop and 
      validate biomarkers and imaging methods to detect early-stage cancers or at-risk 
      individuals. The EDRN is composed of sites that fall into four categories: 
      Biomarker Developmental Laboratories (BDL), Biomarker Reference Laboratories 
      (BRL), Clinical Validation Centers (CVC) and Data Management and Coordinating 
      Centers. Each component has a crucial role to play within the mission of the 
      EDRN. The primary role of the CVCs is to support biomarker developers through 
      validation trials on promising biomarkers discovered by both EDRN and non-EDRN 
      investigators. The second round of funding for the EDRN Lung CVC at Vanderbilt 
      University Medical Center (VUMC) was funded in October 2016 and we intended to 
      accomplish the three missions of the CVCs: To conduct innovative research on the 
      validation of candidate biomarkers for early cancer detection and risk assessment 
      of lung cancer in an observational study; to compare biomarker performance; and 
      to serve as a resource center for collaborative research within the Network and 
      partner with established EDRN BDLs and BRLs, new laboratories and industry 
      partners. This report outlines the impact of the VUMC EDRN Lung CVC and describes 
      the role in promoting and validating biological and imaging biomarkers.
FAU - Kammer, Michael N
AU  - Kammer MN
AD  - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University 
      Medical Center, Nashville, TN, USA.
FAU - Deppen, Stephen A
AU  - Deppen SA
AD  - Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, 
      TN, USA.
AD  - Tennessee Valley Healthcare System, Veterans Affairs, Nashville, TN, USA.
FAU - Antic, Sanja
AU  - Antic S
AD  - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University 
      Medical Center, Nashville, TN, USA.
FAU - Jamshedur Rahman, S M
AU  - Jamshedur Rahman SM
AD  - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University 
      Medical Center, Nashville, TN, USA.
FAU - Eisenberg, Rosana
AU  - Eisenberg R
AD  - Department of Pathology, Microbiology, and Immunology, Vanderbilt University 
      Medical Center, Nashville, TN, USA.
FAU - Maldonado, Fabien
AU  - Maldonado F
AD  - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University 
      Medical Center, Nashville, TN, USA.
FAU - Aldrich, Melinda C
AU  - Aldrich MC
AD  - Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, 
      TN, USA.
AD  - Department of Biomedical Informatics, Vanderbilt University Medical Center, 
      Nashville, TN, USA.
AD  - Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, 
      TN, USA.
FAU - Sandler, Kim L
AU  - Sandler KL
AD  - Department of Radiology, Vanderbilt University Medical Center, Nashville, TN, 
      USA.
FAU - Landman, Bennett
AU  - Landman B
AD  - Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
FAU - Massion, Pierre P
AU  - Massion PP
AD  - Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University 
      Medical Center, Nashville, TN, USA.
AD  - Tennessee Valley Healthcare System, Veterans Affairs, Nashville, TN, USA.
AD  - Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, 
      TN, USA.
FAU - Grogan, Eric L
AU  - Grogan EL
AD  - Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, 
      TN, USA.
AD  - Tennessee Valley Healthcare System, Veterans Affairs, Nashville, TN, USA.
LA  - eng
GR  - U01 CA152662/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - *Biomarkers, Tumor
MH  - *Early Detection of Cancer
MH  - Humans
MH  - *Lung Neoplasms/diagnosis
MH  - Validation Studies as Topic
PMC - PMC10860588
MID - NIHMS1943855
OTO - NOTNLM
OT  - Lung cancer
OT  - biomarkers
OT  - early detection research network
OT  - validation
EDAT- 2022/05/03 06:00
MHDA- 2022/05/04 06:00
PMCR- 2024/02/12
CRDT- 2022/05/02 04:23
PHST- 2022/05/02 04:23 [entrez]
PHST- 2022/05/03 06:00 [pubmed]
PHST- 2022/05/04 06:00 [medline]
PHST- 2024/02/12 00:00 [pmc-release]
AID - CBM210382 [pii]
AID - 10.3233/CBM-210382 [doi]
PST - ppublish
SO  - Cancer Biomark. 2022;33(4):449-465. doi: 10.3233/CBM-210382.